Recruiting equal numbers of indigenous and non-indigenous participants to a ‘polypill’ randomized trial

International Journal for Equity in Health

Anthony Rodgers²  Bruce Arroll⁴  Avinesh Pillai⁵  Chris Bullen⁵  Natasha Rafter⁵  Matire Harwood³  Angela Wadham⁵  C Raina Elley⁴  Sue Crengle¹  Vanessa Selak⁵ 

[1]Waitemata District Health Board, Private Bag 93-503, Takapuna, Auckland, New Zealand

[2]The George Institute for Global Health, Missenden Road, PO Box M201, Camperdown, NSW, 2050, Australia

[3]Te Kupenga Hauora Māori, University of Auckland, Auckland, New Zealand

[4]Department of General Practice and Primary Health Care, University of Auckland, Auckland, New Zealand

[5]National Institute of Health Innovation, University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland, 1142, New Zealand

关键词: Randomized controlled trial;    Primary care;    Polypill;    Indigenous;    Cardiovascular disease;    Inequalities;   

Others  :  824751
DOI  :  10.1186/1475-9276-12-44

 received in 2013-02-10, accepted in 2013-06-18,  发布年份 2013

【 摘 要 】

Introduction

Māori are disproportionately affected by cardiovascular disease (CVD), which is the main reason for the eight year difference in life expectancy between Māori and non-Māori. The primary care-based IMPACT (IMProving Adherence using Combination Therapy) trial evaluates whether fixed dose combination therapy (a “polypill”) improves adherence to guideline-based therapy compared with current care among people at high risk of CVD. Interventions shown in trials to be effective do not necessarily reduce ethnic disparities, and may in fact widen them. Indigenous populations with poorer health outcomes are often under-represented in trials so the effect of interventions cannot be assessed for them, specifically. Therefore, the IMPACT trial aimed to recruit as many Māori as non-Māori to assess the consistency of the effect of the polypill. This paper describes the methods and results of the recruitment strategy used to achieve this.

Methods

Experienced Māori researchers were involved in trial governance throughout trial development and conduct. The trial Steering Committee included leading Māori researchers and was committed to equal recruitment of Māori and non-Māori. Additional funding and Māori research nurses were sought to allow home-based assessment, establishment of the relationship between research nurse and participant, more family involvement prior to enrollment, continuity of the research nurse-participant relationship, and acknowledgement of other Māori culturally important procedures, interactions, language and manners. Primary care practices with high enrollment of Māori were targeted, with over-sampling of potentially eligible Māori patients, lower thresholds for screening of Māori and 6 months continued Māori recruitment after non-Māori recruitment had finished.

Results

A total of 257 Māori and 256 non-Māori participants were randomized. Four Māori and eight non-Māori participants were randomized per research nurse per month. Potentially eligible Māori were more likely than non-Māori to proceed to subsequent stages of recruitment. Differences between randomized Māori and non-Māori were evident (e.g. Maori were less likely to have established coronary artery disease).

Conclusions

Recruitment of equal numbers of indigenous and non-indigenous participants is possible if it is prioritised, adequately resourced and self-determination is supported.

Trial registration

The trial is registered with the Australian New Zealand Clinical Trial Registry ACTRN12606000067572

【 授权许可】

   
2013 Selak et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]United Nations: United Nations declaration on the rights of indigenous peoples . Geneva: United Nations; 2007.
• [2]Read the Treaty. URL: http://www.nzhistory.net.nz/politics/treaty/read-the-treaty/english-text webcite, updated 20 Dec 2012
• [3]Chan WC, Wright C, Riddell T, Wells S, Kerr AJ, Gala G, Jackson R: Ethnic and socioeconomic disparities in the prevalence of cardiovascualar disease in New Zealand. NZMJ 2008, 121(1285):11-20.
• [4]Robson B, Harris R (Eds): Hauora. Maori standards of health IV. A study of the years 2000–2005. Wellington: Te Ropu Rangahau Hauora a Eru Pomare; 2007.
• [5]Blakely T, Tobias M, Robson B, Ajwani S, Bonne M, Woodward A: Widening ethnic mortality disparities in New Zealand 1981–99. Soc Sci Med 2005, 61:2233-2251.
• [6]Anderson I, Crengle S, Kamaka ML, Chen TH, Palafox N, Jackson-Pulver L: Indigenous health in Australia, New Zealand, and the Pacific. Lancet 2006, 367:1775-1785.
• [7]Cunningham M: Health (Chapter V). In State of the World's Indigenous Peoples. Edited by Department of Economic and Social Affairs. Geneva: United Nations; 2009.
• [8]Selak V, Elley C, Crengle S, Harwood M, Doughty R, Arroll B, Bryant L, Rafter N, Vander Hoorn S, Wadham A, et al.: Improving adherence using combination therapy (IMPACT): Design and protocol of a randomised controlled trial in primary care. Contemp Clin Trials 2011, 32:909-915.
• [9]Bramley D, Riddell T, Crengle S, Curtis E, Harwood M, Nehua D, Reid P: A call to action on Maori cardiovascular health. N Z Med J 2004, 117(1197):U957.
• [10]Robson B: Mana Whakamarama - equal explanatory power: Maori and non-Maori sample size in national health surveys. Wellington: Te Ropu Rangahau Hauora a Eru Pomare, Wellington School of Medicine and Health Sciences, University of Otago for Public Health Intelligence, Ministry of Health, New Zealand; 2002.
• [11]Ni Mhurchu C, Blakely T, Funaki-Tahifote M, McKerchar C, Wilton J, Chua S, Jiang Y: Inclusion of indigenous and ethnic minority populations in intervention trials: challenges and strategies in a New Zealand supermarket study. J Epidemiol Community Health 2009, 63:850-855.
• [12]Sibthorpe B, Bailie RS, Brady MA, Ball SA, Sumner-Dodd P, Hall WD: The demise of a planned randomised controlled trial in an urban Aboriginal medical service. Medical Journal of Australia 2002, 176:273-276.
• [13]Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, Tilburt J, Baffi C, Tanpitukpongse TP, Wilson RF, et al.: Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 2007, 111(2):228-42.
• [14]Health Information for Action Team: Waitemata health needs assessment 2009: Health and health care of Waitemata Residents. North Shore City, Auckland, New Zealand: Waitemata District Health Board; 2009.
• [15]Blundell R, Gibbons V, Lillis S: Cultural issues in research, a reflection. N Z Med J 2010, 123(1309):97-105.
• [16]New Zealand Guidelines Group: Evidence-based best practice guideline. The assessment and management of cardiovascular risk. Wellington, New Zealand: New Zealand Guidelines Group; 2003.
• [17]Selak V, Elley CR, Wells S, Rodgers A, Sharpe N: Aspirin for primary prevention: yes or no? J Prim Health Care 2010, 2(2):92-99.
• [18]Ministry of Health: Ethnicity data protocols for the health and disability sector. New Zealand: Wellington: Ministry of Health; 2004.
• [19]Department of Statistics: Guidelines for use of the non-Māori group in ethnic statistics. Wellington, New Zealand; 2009.
• [20]Coppell KJ, Mann JI, Williams SM, Jo E, Drury PL, Miller JC, Parnell WR: Prevalence of diagnosed and undiagnosed diabetes and prediabetes in New Zealand: findings from the 2008/09 Adult Nutrition Survey. N Z Med J 2013, 126(1370):23-42.